Merck/Sigma-Aldrich: the 200,000 products case* In a nutshell: In the life science case Merck/Sigma-Aldrich, the Commission focused for the first time on "laboratory chemicals", a term that covers hundreds of thousands of specialty chemicals. The Commission identified concerns regarding the supply of solvents and inorganics on the basis of a largely qualitative analysis based on closeness of competition. The concerns were solved in phase I with a tailored upfront buyer remedy covering the entire supply chain. I. Overview of the case In June 2015, the Commission cleared the acquisition by Merck KGaA of Germany (Merck) of the US life science company SigmaAldrich Corporation (Sigma), subject to remedies. The main rationale of this transaction was to broaden and diversify Merck's life
Share on
|
|
The EU Commission conditionally approves the acquisition of a life science company affecting the market for laboratory chemicals (Merck / Sigma-Aldrich)
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
